


# Product Development Partnerships (PDPs)

---



- There has historically been little financial incentive for private sector product developers to invest in developing the innovative solutions for neglected diseases.
- Late 1990s and early 2000s: a movement of stakeholders came together to forge new models to address acute global health needs.
- The response to this movement led to a wave of PDPs. Examples of the PDPs are listed on the left.


# Product Development Partnerships (PDPs)

---




- There has historically been little financial incentive for private sector product developers to invest in developing the innovative solutions for neglected diseases.
- Late 1990s and early 2000s: a movement of stakeholders came together to forge new models to address acute global health needs.
- The response to this movement led to a wave of PDPs. Examples of the PDPs are listed on the left.

# How PDPs work?



- A non-profit organization that develops innovative and affordable medicines and tools for populations affected by poverty-related and neglected tropical diseases.
- Products focus on un-met patients needs for the use in low- and middle- income countries.
- Building partnerships between the public, private, academic, and philanthropic sectors

# Innovations led by PDPs



# PDPs' Critical Role beyond the Neglected Diseases

## Keeping the Promise

Product Development Partnerships' Role in the New Age of Health Research and Product Development



- PDPs has helped strengthen health systems and promoted health security in endemic countries, contributed to progress toward the United Nations 2030 Sustainable Development Goals (SDGs)
- Increased global capacity to conduct research.

# GHIT Portfolio as of September 2021

## Discovery

## Preclinical

## Clinical

Drugs / Vaccines


Diagnostics



<p><b>Buruli ulcer</b></p> <p><b>Chagas disease</b></p> <p><b>Mycetoma</b></p>	<p><b>Chagas disease, Leishmaniasis</b></p>	<p><b>Chagas disease, Leishmaniasis</b></p>	<p><b>Chagas disease</b></p> <p><b>Leishmaniasis</b></p>	<p><b>Dengue fever</b></p> <p><b>Leishmaniasis</b></p> <p><b>Lymphatic filariasis, Onchocerciasis</b></p> <p><b>Soil-transmitted helminths</b></p>	<p><b>Cutaneous leishmaniasis</b></p> <p><b>Schistosomiasis</b></p>	<p><b>Mycetoma</b></p>	<p><b>Schistosomiasis</b></p>
--	---	---	--	--	---	------------------------	-------------------------------



--	--	--	--	--	--



--	--

# GHIT Portfolio as of September 2021

## Discovery

## Preclinical

## Clinical

Drugs / Vaccines

Target Research

Screening

Hit-to-Lead

Lead Optimization

Preclinical

Phase I

Phase II

Phase III

Registration

Diagnostics

Target Research

Product Design

Product Development

Product Validation

Product Validation

Registration



NTDs

Buruli ulcer



Chagas disease



Mycetoma



Chagas disease, Leishmaniasis



Chagas disease, Leishmaniasis



Chagas disease



Leishmaniasis



Dengue fever



Leishmaniasis



Lymphatic filariasis, Onchocerciasis



Soil-transmitted helminths



Cutaneous leishmaniasis



Schistosomiasis







Mycetoma



Schistosomiasis



Malaria



Tuberculosis

